Showing 10–18 of 24 results
-

د.إ3,400.00
The Fragile X (FMR1) Mutation Screen (L) is a genetic test designed to detect mutations in the FMR1 gene, which are associated with Fragile X syndrome, a leading cause of inherited intellectual disability and autism. This screening identifies CGG repeat expansions, distinguishing between normal, premutation, and full mutation alleles. Key benefits include early detection for informed reproductive decisions, risk assessment for carriers, and guidance for personalized medical management. Utilizing advanced molecular techniques, the test ensures high accuracy and reliability. Ideal for individuals with a family history of Fragile X or unexplained developmental delays, this screening provides critical genetic insights for proactive healthcare planning.
-

د.إ1,950.00
The Hepatitis B Virus – Qualitative (PCR) test is a highly sensitive molecular diagnostic tool designed to detect the presence of Hepatitis B viral DNA in a patient’s blood. Utilizing advanced Polymerase Chain Reaction (PCR) technology, it offers early and accurate detection of active HBV infection, even at low viral loads.
Sample Type : 4 mL EDTA plasma or Serum
Methodology : Real-time PCR
TAT : 2 Days
-

د.إ2,820.00
The HER-2/NEU – FISH Test is a highly precise diagnostic tool used to detect HER-2 gene amplification in breast cancer and other malignancies. Utilizing Fluorescence In Situ Hybridization (FISH) technology, it provides accurate, reliable, and early detection of HER-2 status, which is crucial for determining targeted therapy eligibility, such as Herceptin (trastuzumab) treatment. This test offers higher sensitivity and specificity compared to immunohistochemistry (IHC), reducing false-positive or false-negative results. Its rapid turnaround time and clinically validated methodology make it a gold standard for personalized cancer treatment, ensuring optimal therapeutic decisions and improved patient outcomes.
-

د.إ4,000.00
The **Hereditary Cancer Gene Panel (57 ACMG Genes)** is a comprehensive genetic test designed to assess inherited cancer risk by analyzing 57 clinically significant genes recommended by the **American College of Medical Genetics (ACMG)**. This panel identifies mutations linked to various hereditary cancers, including **breast, ovarian, colorectal, prostate, and pancreatic cancers**, enabling early detection and personalized risk management. Key features include **next-generation sequencing (NGS) technology** for high accuracy, expert-reviewed results, and actionable insights for **preventive care and targeted treatment strategies**. Ideal for individuals with a family history of cancer, this test empowers proactive healthcare decisions, offering **lifelong benefits through early intervention and precision medicine**.
-

د.إ4,000.00
The **Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 Literature-Reviewed Genes** is a comprehensive genetic test designed to assess hereditary cancer risk. It analyzes **57 key genes**, including the **ACMG 20** and **HBOC-related genes**, alongside **865 literature-reviewed genes**, ensuring a thorough evaluation of cancer predisposition. This panel covers a wide range of hereditary cancers, including **breast, ovarian, colorectal, and more**, providing **clinically actionable insights** for early detection and personalized risk management. Utilizing **advanced sequencing technology**, it delivers **high accuracy and reliability**, making it an essential tool for **patients, healthcare providers, and genetic counselors**. Its unique combination of **expert-curated genes and extensive literature review** enhances diagnostic precision, setting it apart as a **cutting-edge solution for hereditary cancer risk assessment**.
-

د.إ750.00
Sample Type : Serum
Methodology : Electrophoresis
TAT : 10 Days
-

د.إ1,250.00
Sample Type : Whole Blood
Methodology : Real-time PCR
TAT : 10 Days
-

د.إ2,720.00
The Jak 2 Exon 12-15 Mutation Analysis is a specialized genetic test designed to detect mutations in exons 12-15 of the JAK2 gene, which are associated with myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV) and other hematologic disorders. This test offers high sensitivity and specificity, enabling early and accurate diagnosis, which is crucial for targeted treatment decisions and disease monitoring. Unlike standard JAK2 V617F mutation tests, this analysis identifies rare but clinically significant mutations, providing comprehensive genetic profiling for patients with suspected MPNs. Its advanced molecular technology ensures reliable results, supporting personalized therapeutic strategies and improving patient outcomes.
-

د.إ13,000.00
Liquid HALLMARK is a comprehensive liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a simple blood draw to detect and monitor cancer.
Sample Type : Serum
Methodology : Ultra-deep sequencing using Lucence’s proprietary AmpliMARK™ technology
TAT : 8-10 Days